Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

(marketscreener.com) Equillium, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the...https://www.marketscreener.com/quote/stock/EQUILLIUM-INC-46555746/news/Equillium-Announces-Abstract-Accepted-for-Oral-Presentation-at-the-Transplantation-Cellular-Therap-42728510/?utm_medium=RSS&utm_content=20230113